Prognostic Factors of Patients with Pathologic Stage I Lung Adenocarcinoma

Overview

Journal J Thorac Dis

Publisher AME Publishing Company

Specialty Pulmonary Medicine

Date 2018 Jun 1

PMID 29850191

Citations 1

Authors

Ying-Yi Chen

Tsai-Wang Huang

Affiliations

Soon will be listed here.

Citing Articles

Lymph node micrometastasis in N stage: a call for more evidence.

Ren Y, Dai C, Xie H, She Y, Su H, Chen C J Thorac Dis. 2018; 10(Suppl 18):S2219-S2220.

PMID: 30123567 PMC: 6072940. DOI: 10.21037/jtd.2018.06.57.

References

Anagnostou V, Syrigos K, Bepler G, Homer R, Rimm D . Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma. J Clin Oncol. 2008; 27(2):271-8. DOI: 10.1200/JCO.2008.17.0043. View

Yi E, Bae M, Cho S, Chung J, Jheon S, Kim K . Pathological prognostic factors of recurrence in early stage lung adenocarcinoma. ANZ J Surg. 2017; 88(4):327-331. DOI: 10.1111/ans.14033. View

Yang X, Liu Y, Lian F, Guo L, Wen P, Liu X . Lepidic and micropapillary growth pattern and expression of Napsin A can stratify patients of stage I lung adenocarcinoma into different prognostic subgroup. Int J Clin Exp Pathol. 2014; 7(4):1459-68. PMC: 4014225. View

Xu P, Zhao M, Liu Z, Liu Y, Chen Y, Luo R . Elevated nuclear CCND1 expression confers an unfavorable prognosis for early stage lung adenocarcinoma patients. Int J Clin Exp Pathol. 2016; 8(12):15887-94. PMC: 4730073. View

Makimoto Y, Nabeshima K, Iwasaki H, Miyoshi T, Enatsu S, Shiraishi T . Micropapillary pattern: a distinct pathological marker to subclassify tumours with a significantly poor prognosis within small peripheral lung adenocarcinoma (</=20 mm) with mixed bronchioloalveolar and invasive subtypes (Noguchi's type C tumours). Histopathology. 2005; 46(6):677-84. DOI: 10.1111/j.1365-2559.2005.02126.x. View

Sun Y, Hou L, Yang Y, Xie H, Yang Y, Li Z . Two-gene signature improves the discriminatory power of IASLC/ATS/ERS classification to predict the survival of patients with early-stage lung adenocarcinoma. Onco Targets Ther. 2016; 9:4583-91. PMC: 4966694. DOI: 10.2147/OTT.S107272. View

Shiono S, Abiko M, Okazaki T, Chiba M, Yabuki H, Sato T . Positron emission tomography for predicting recurrence in stage I lung adenocarcinoma: standardized uptake value corrected by mean liver standardized uptake value. Eur J Cardiothorac Surg. 2011; 40(5):1165-9. DOI: 10.1016/j.ejcts.2011.02.041. View

Shiono S, Yanagawa N . Spread through air spaces is a predictive factor of recurrence and a prognostic factor in stage I lung adenocarcinoma. Interact Cardiovasc Thorac Surg. 2016; 23(4):567-72. DOI: 10.1093/icvts/ivw211. View

Kamiya K, Hayashi Y, Douguchi J, Hashiguchi A, Yamada T, Izumi Y . Histopathological features and prognostic significance of the micropapillary pattern in lung adenocarcinoma. Mod Pathol. 2008; 21(8):992-1001. DOI: 10.1038/modpathol.2008.79. View

10.

Sakao Y, Tomimitsu S, Takeda Y, Natsuaki M, Itoh T . Carcinoembryonic antigen as a predictive factor for postoperative tumor relapse in early-stage lung adenocarcinoma. Eur J Cardiothorac Surg. 2004; 25(4):520-2. DOI: 10.1016/j.ejcts.2004.01.029. View

11.

Xu C, Wang W, Wei Y, Hu H, Zou J, Yan J . Prognostic value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification in stage IB lung adenocarcinoma. Eur J Surg Oncol. 2015; 41(10):1430-6. DOI: 10.1016/j.ejso.2015.06.004. View

12.

Seki N, Takasu T, Sawada S, Nakata M, Nishimura R, Segawa Y . Prognostic significance of expression of eukaryotic initiation factor 4E and 4E binding protein 1 in patients with pathological stage I invasive lung adenocarcinoma. Lung Cancer. 2010; 70(3):329-34. DOI: 10.1016/j.lungcan.2010.03.006. View

13.

Kadota K, Nitadori J, Sarkaria I, Sima C, Jia X, Yoshizawa A . Thyroid transcription factor-1 expression is an independent predictor of recurrence and correlates with the IASLC/ATS/ERS histologic classification in patients with stage I lung adenocarcinoma. Cancer. 2012; 119(5):931-8. PMC: 3691693. DOI: 10.1002/cncr.27863. View

14.

Isobe T, Hiyama K, Yoshida Y, Fujiwara Y, Yamakido M . Prognostic significance of p53 and ras gene abnormalities in lung adenocarcinoma patients with stage I disease after curative resection. Jpn J Cancer Res. 1994; 85(12):1240-6. PMC: 5919395. DOI: 10.1111/j.1349-7006.1994.tb02936.x. View

15.

Pelosi G, Barisella M, Pasini F, Elena Leon M, Veronesi G, Spaggiari L . CD117 immunoreactivity in stage I adenocarcinoma and squamous cell carcinoma of the lung: relevance to prognosis in a subset of adenocarcinoma patients. Mod Pathol. 2004; 17(6):711-21. DOI: 10.1038/modpathol.3800110. View

16.

Kadota K, Yeh Y, Villena-Vargas J, Cherkassky L, Drill E, Sima C . Tumor Budding Correlates With the Protumor Immune Microenvironment and Is an Independent Prognostic Factor for Recurrence of Stage I Lung Adenocarcinoma. Chest. 2015; 148(3):711-721. PMC: 4556124. DOI: 10.1378/chest.14-3005. View

17.

Noro R, Honda K, Tsuta K, Ishii G, Maeshima A, Miura N . Distinct outcome of stage I lung adenocarcinoma with ACTN4 cell motility gene amplification. Ann Oncol. 2013; 24(10):2594-2600. DOI: 10.1093/annonc/mdt293. View

18.

Mizuno T, Ishii G, Nagai K, Yoshida J, Nishimura M, Mochizuki T . Identification of a low risk subgroup of stage IB lung adenocarcinoma patients. Lung Cancer. 2008; 62(3):302-8. DOI: 10.1016/j.lungcan.2008.03.032. View

19.

De Oliveira Duarte Achcar R, Nikiforova M, Yousem S . Micropapillary lung adenocarcinoma: EGFR, K-ras, and BRAF mutational profile. Am J Clin Pathol. 2009; 131(5):694-700. DOI: 10.1309/AJCPBS85VJEOBPDO. View

20.

Funai K, Sugimura H, Morita T, Shundo Y, Shimizu K, Shiiya N . Lymphatic vessel invasion is a significant prognostic indicator in stage IA lung adenocarcinoma. Ann Surg Oncol. 2011; 18(10):2968-72. DOI: 10.1245/s10434-011-1729-9. View